Advances in the treatment of idiopathic pulmonary fibrosis

Bibliography

• Baumgartner KB, Samet JM, Stidley CA, et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155:242–248.
   PubMed Web of Science ®Google Scholar
• Iwai K, Mori T, Yamada N, et al. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med. 1994;150:670–675.
   PubMed Web of Science ®Google Scholar
• Hubbard R, Lewis S, Richards K, et al. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet. 1996;347:284–289.
   PubMed Web of Science ®Google Scholar
• Johnston ID, Prescott RJ, Chalmers JC, et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax. 1997;52:38–44.
   PubMed Web of Science ®Google Scholar
• Hubbard R, Cooper M, Antoniak M, et al. Risk of cryptogenic fibrosing alveolitis in metal workers. Lancet. 2000;355:466–467.
   PubMed Web of Science ®Google Scholar
• Gustafson T, Dahlman-Höglund A, Nilsson K, et al. Occupational exposure and severe pulmonary fibrosis. Respir Med. 2007;101:2207–2212.
   PubMed Web of Science ®Google Scholar
• Tobin RW, Pope CE 2nd, Pellegrini CA et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158:1804–1808.
   PubMed Web of Science ®Google Scholar
• Enomoto T, Usuki J, Azuma A, et al. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest. 2003;123:2007–2011.
   PubMed Web of Science ®Google Scholar
• Ueda T, Ohta K, Suzuki N, et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis. 1992;146:266–268.
   PubMed Web of Science ®Google Scholar
• Egan JJ, Stewart JP, Hasleton PS, et al. Epstein–Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax. 1995;50:1234–1239.
   PubMed Web of Science ®Google Scholar
• Tang YW, Johnson JE, Browning PJ, et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol. 2003;41:2633–2640.
   PubMed Web of Science ®Google Scholar
• Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007;356:1317–1326.
   PubMed Web of Science ®Google Scholar
• Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178:729–737.
   PubMed Web of Science ®Google Scholar
• Tsang AR, Wyatt HD, Ting NS, et al. hTERT mutations associated with idiopathic pulmonary fibrosis affect telomerase activity, telomere length, and cell growth by distinct mechanisms. Aging Cell. 2012;11:482–490.
   PubMed Web of Science ®Google Scholar
• Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364:1503–1512.
   PubMed Web of Science ®Google Scholar
• Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet. 2009;84:52–59.
   PubMed Web of Science ®Google Scholar
• Van Moorsel CH, van Oosterhout MF, Barlo NP, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort. Am J Respir Crit Care Med. 2010;182:1419–1425.
   PubMed Web of Science ®Google Scholar
• Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150:967–972.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164:1171–1181.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646–664.
   PubMed Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192:e3–e19.
   PubMed Web of Science ®Google Scholar
• Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246:697–722.
   PubMed Web of Science ®Google Scholar
• Raghu G, Lynch D, Godwin JD, et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet. Respiratory Med. 2014;2:277–284.
   PubMed Web of Science ®Google Scholar
• Mathieson JR, Mayo JR, Staples CA, et al. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology. 1989;171:111–116.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164:193–196.
   PubMed Web of Science ®Google Scholar
• Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med. 2000;161:1172–1178.
   PubMed Web of Science ®Google Scholar
• Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199–203.
   PubMed Web of Science ®Google Scholar
• Rudd RM, Prescott RJ, Chalmers JC, et al. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic, S. British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax. 2007;62:62–66.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001;164:1025–1032.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142:963–967.
   PubMed Web of Science ®Google Scholar
• Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–643.
   PubMed Web of Science ®Google Scholar
• Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27:143–150.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092.
   PubMed Web of Science ®Google Scholar
• Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082.
   PubMed Web of Science ®Google Scholar
• Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810–816.
   PubMed Web of Science ®Google Scholar
• Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. 2010;137:129–137.
   PubMed Web of Science ®Google Scholar
• Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:980–985.
   PubMed Web of Science ®Google Scholar
• Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax. 2011;66:462–467.
   PubMed Web of Science ®Google Scholar
• Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 2007;176:277–284.
   PubMed Web of Science ®Google Scholar
• Hutchinson JP, McKeever TM, Fogarty AW, et al. Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. Ann Am Thorac Soc. 2014;11:1176–1185.
   PubMedGoogle Scholar
• Blackwell TS, Tager AM, Borok Z, et al. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med. 2014;189:214–222.
   PubMed Web of Science ®Google Scholar
• Englert JM, Hanford LE, Kaminski N, et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol. 2008;172:583–591.
   PubMed Web of Science ®Google Scholar
• Samuel CS, Zhao C, Bathgate RA, et al. Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. Faseb. 2003;17:121–123.
   PubMedGoogle Scholar
• Pierce EM, Carpenter K, Jakubzick C, et al. Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice. Am J Pathol. 2007;170:1152–1164.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Davies HR, Ferrara G, et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Systematic Rev. 2003;3:CD002880.
   Google Scholar
• Winterbauer RH, Hammar SP, Hallman KO, et al. Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med. 1978;65:661–672.
   PubMed Web of Science ®Google Scholar
• Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis. 1991;144:291–296.
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–1977.
   PubMed Web of Science ®Google Scholar
• Solis-Herruzo JA, Brenner DA, Chojkier M. Tumor necrosis factor alpha inhibits collagen gene transcription and collagen synthesis in cultured human fibroblasts. J Biol Chem. 1988;263:5841–5845.
   PubMed Web of Science ®Google Scholar
• Kahari VM, Chen YQ, Su MW, et al. Tumor necrosis factor-alpha and interferon-gamma suppress the activation of human type I collagen gene expression by transforming growth factor-beta 1. Evidence for two distinct mechanisms of inhibition at the transcriptional and posttranscriptional levels. J Clin Invest. 1990;86:1489–1495.
   PubMed Web of Science ®Google Scholar
• Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res. 2000;86:1259–1265.
   PubMed Web of Science ®Google Scholar
• Greenwel P, Tanaka S, Penkov D, et al. Tumor necrosis factor alpha inhibits type I collagen synthesis through repressive CCAAT/enhancer-binding proteins. Mol Cell Biol. 2000;20:912–918.
   PubMed Web of Science ®Google Scholar
• Han YP, Tuan TL, Wu H, et al. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci. 2001;114:131–139.
   PubMed Web of Science ®Google Scholar
• Rapala KT, Vaha-Kreula MO, Heino JJ, et al. Tumor necrosis factor-alpha inhibits collagen synthesis in human and rat granulation tissue fibroblasts. Experientia. 1996;52:70–74.
   PubMedGoogle Scholar
• Kon A, Vindevoghel L, Kouba DJ, et al. Cooperation between SMAD and NF-kappaB in growth factor regulated type VII collagen gene expression. Oncogene. 1999;18:1837–1844.
   PubMed Web of Science ®Google Scholar
• Chou DH, Lee W, McCulloch CA. TNF-alpha inactivation of collagen receptors: implications for fibroblast function and fibrosis. J Immunol. 1996;156:4354–4362.
   PubMed Web of Science ®Google Scholar
• Abraham DJ, Shiwen X, Black CM, et al. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem. 2000;275:15220–15225.
   PubMed Web of Science ®Google Scholar
• Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J. 1994;7:515–518.
   PubMed Web of Science ®Google Scholar
• Piguet PF, Collart MA, Grau GE, et al. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature. 1990;344:245–247.
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008;178:948–955.
   PubMed Web of Science ®Google Scholar
• Rosenbloom J, Feldman G, Freundlich B, et al. Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels. Arthritis Rheum. 1986;29:851–856.
   PubMed Web of Science ®Google Scholar
• Elias JA, Jimenez SA, Freundlich B. Recombinant gamma, alpha, and beta interferon regulation of human lung fibroblast proliferation. Am Rev Respir Dis. 1987;135:62–65.
   PubMed Web of Science ®Google Scholar
• Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res. 1995;21:791–808.
   PubMed Web of Science ®Google Scholar
• Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999;341:1264–1269.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009;374:222–228.
   PubMed Web of Science ®Google Scholar
• Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007;131:897–899.
   PubMed Web of Science ®Google Scholar
• Jackson RM, Glassberg MK, Ramos CF, et al. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung. 2010;188:115–123.
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363:620–628.
   PubMed Web of Science ®Google Scholar
• Peacock AJ, Dawes KE, Shock A, et al. Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am J Respir Cell Mol Biol. 1992;7:492–499.
   PubMed Web of Science ®Google Scholar
• Shahar I, Fireman E, Topilsky M, et al. Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol. 1999;21:759–775.
   PubMed Web of Science ®Google Scholar
• Xu S, Denton CP, Holmes A, et al. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S360–363.
   PubMed Web of Science ®Google Scholar
• Saleh D, Furukawa K, Tsao MS, et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol. 1997;16:187–193.
   PubMed Web of Science ®Google Scholar
• Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet. 1993;341:1550–1554.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75–81.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:92–99.
   PubMed Web of Science ®Google Scholar
• Corte TJ, Keir GJ, Dimopoulos K, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2014;190:208–217.
   PubMed Web of Science ®Google Scholar
• Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013;42:1622–1632.
   PubMed Web of Science ®Google Scholar
• Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013;158:641–649.
   PubMed Web of Science ®Google Scholar
• Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1989;139:370–372.
   PubMed Web of Science ®Google Scholar
• Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med. 1997;156:1897–1901.
   PubMed Web of Science ®Google Scholar
• Behr J, Demedts M, Buhl R, et al. Lung function in idiopathic pulmonary fibrosis–extended analyses of the IFIGENIA trial. Respir Res. 2009;10:101.
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2093–2101.
   PubMed Web of Science ®Google Scholar
• Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med. 2008;178:1257–1261.
   PubMed Web of Science ®Google Scholar
• Sprunger DB, Olson AL, Huie TJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J. 2012;39:125–132.
   PubMed Web of Science ®Google Scholar
• Imokawa S, Sato A, Hayakawa H, et al. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med. 1997;156:631–636.
   PubMed Web of Science ®Google Scholar
• Gunther A, Mosavi P, Ruppert C, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost. 2000;83:853–860.
   PubMed Web of Science ®Google Scholar
• Chambers RC, Scotton CJ. Coagulation cascade proteinases in lung injury and fibrosis. Proc Am Thorac Soc. 2012;9:96–101.
   PubMedGoogle Scholar
• Gunther A, Lübke N, Ermert M, et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med. 2003;168:1358–1365.
   PubMed Web of Science ®Google Scholar
• Howell DC, Goldsack NR, Marshall RP, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol. 2001;159:1383–1395.
   PubMed Web of Science ®Google Scholar
• Kout M, Brabec V. Agglutinating phenomenon in the rat sera after administration of methylcellulose. Folia Haematologica. 1980;107:782–786.
   Google Scholar
• Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005;128:1475–1482.
   PubMed Web of Science ®Google Scholar
• Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186:88–95.
   PubMed Web of Science ®Google Scholar
• Kumagai S, Ohtani H, Nagai T, et al. Platelet-derived growth factor and its receptors are expressed in areas of both active inflammation and active fibrosis in inflammatory bowel disease. Tohoku J Exp Med. 2001;195:21–33.
   PubMed Web of Science ®Google Scholar
• Seppa H, Grotendorst G, Seppa S, et al. Platelet-derived growth factor in chemotactic for fibroblasts. J Cell Biol. 1982;92:584–588.
   PubMed Web of Science ®Google Scholar
• Lo RS, Lecocq M, Uwambayinema F, et al. Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis. Am J Respir Crit Care Med. 2011;184:1270–1281.
   PubMed Web of Science ®Google Scholar
• Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004;15:255–273.
   PubMed Web of Science ®Google Scholar
• Vuorinen K, Gao F, Oury TD, et al. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res. 2007;33:357–373.
   PubMed Web of Science ®Google Scholar
• Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114:1308–1316.
   PubMed Web of Science ®Google Scholar
• Vittal R, Zhang H, Han MK, et al. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J Pharmacol Exp Ther. 2007;321:35–44.
   PubMed Web of Science ®Google Scholar
• Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010;181:604–610.
   PubMed Web of Science ®Google Scholar
• Antoniu SA, Kolb MR. Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs: Investigational Drugs J. 2010;13:332–345.
   PubMed Web of Science ®Google Scholar
• Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29:976–985.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079–1087.
   PubMed Web of Science ®Google Scholar
• Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation. 2000;24:477–491.
   PubMed Web of Science ®Google Scholar
• Giri SN, Leonard S, Shi X, et al. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathology, Toxicol Oncol: Official Organ Int Soc Environ Toxicol Cancer. 1999;18:169–177.
   PubMedGoogle Scholar
• Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol. 1999;276:L311–318.
   PubMed Web of Science ®Google Scholar
• Di Sario A, Bendia E, Svegliati Baroni G, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol. 2002;37:584–591.
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040–1047.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–829.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–1769.
   PubMed Web of Science ®Google Scholar
• Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med. 2011;184:842–847.
   PubMed Web of Science ®Google Scholar
• Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients. Chron Respir Dis. 2011;8:225–231.
   PubMed Web of Science ®Google Scholar
• Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980;93:391–398.
   PubMed Web of Science ®Google Scholar
• Morrison DA, Stovall JR. Increased exercise capacity in hypoxemic patients after long-term oxygen therapy. Chest. 1992;102:542–550.
   PubMed Web of Science ®Google Scholar
• Kolilekas L, Manali E, Vlami KA, et al. Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J Clin Sleep Med. 2013;9:593–601.
   PubMed Web of Science ®Google Scholar
• Clark M, Cooper B, Singh S, et al. A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. Thorax. 2001;56:482–486.
   PubMed Web of Science ®Google Scholar
• Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report–2010. J Heart Lung Transplantation: Official Publication Int Soc Heart Transplantation. 2010;29:1104–1118.
   PubMed Web of Science ®Google Scholar
• Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update–a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplantation: Official Publication Int Soc Heart Transplantation. 2006;25:745–755.
   PubMed Web of Science ®Google Scholar
• Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg. 2003;126:469–475.
   PubMed Web of Science ®Google Scholar
• Meyers BF, Lynch JP, Trulock EP, et al. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J Thorac Cardiovasc Surg. 2000;120:99–107.
   PubMed Web of Science ®Google Scholar
• Weiss ES, Allen JG, Merlo CA, et al. Lung allocation score predicts survival in lung transplantation patients with pulmonary fibrosis. Ann Thorac Surg. 2009;88:1757–1764.
   PubMed Web of Science ®Google Scholar
• Mason DP, Brizzio ME, Alster JM, et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg. 2007;84:1121–1128.
   PubMed Web of Science ®Google Scholar
• Cooper JD, Goldman BS, Goldberg M. Experience with single-lung transplantation for pulmonary fibrosis. The Toronto Lung Transplant Group. JAMA. 1988;259:2258–2262.
   PubMed Web of Science ®Google Scholar
• Grossman RF, Frost A, Zamel N, et al. Results of single-lung transplantation for bilateral pulmonary fibrosis. The Toronto Lung Transplant Group. N Engl J Med. 1990;322:727–733.
   PubMed Web of Science ®Google Scholar
• Trulock EP, Edwards LB, Taylor DO, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult lung and heart-lung transplant report–2004. J Heart Lung Transplantation: Official Publication Int Soc Heart Transplantation. 2004;23:804–815.
   PubMed Web of Science ®Google Scholar
• Meyer DM, Edwards LB, Torres F, et al. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg. 2005;79:950–957.
   PubMed Web of Science ®Google Scholar
• Ong KC, Wong WP, Jailani AR, et al. Effects of a pulmonary rehabilitation programme on physiologic and psychosocial outcomes in patients with chronic respiratory disorders. Ann Acad Med Singapore. 2001;30:15–21.
   PubMed Web of Science ®Google Scholar
• Huppmann P, Sczepanski B, Boensch M, et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J. 2013;42:444–453.
   PubMed Web of Science ®Google Scholar
• Holland AE, Hill CJ, Glaspole I, et al. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med. 2012;106:429–435.
   PubMed Web of Science ®Google Scholar
• Ferreira A, Garvey C, Connors GL, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest. 2009;135:442–447.
   PubMed Web of Science ®Google Scholar
• Potter MN, Mott MG, Oakhill A. Granulocyte-macrophage colony-stimulating factor (GM-CSF), hypocalcemia, and hypomagnesemia. Ann Intern Med. 1990;112:715.
   PubMed Web of Science ®Google Scholar
• Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:1390–1394.
   PubMed Web of Science ®Google Scholar
• Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet. Respiratory Med. 2013;1:369–376.
   PubMed Web of Science ®Google Scholar
• Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir Med. 2008;102:1355–1359.
   PubMed Web of Science ®Google Scholar
• Vianello A, Arcaro G, Battistella L, et al. Noninvasive ventilation in the event of acute respiratory failure in patients with idiopathic pulmonary fibrosis. J Crit Care. 2014;29:562–567.
   PubMed Web of Science ®Google Scholar
• Allen S, Raut S, Woollard J, et al. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat Med. 2005;19:128–130.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Donesky D, Pantilat SZ, et al. Dyspnea in idiopathic pulmonary fibrosis: a systematic review. J Pain Symptom Manage. 2012;43:771–782.
   PubMed Web of Science ®Google Scholar
• Lanken PN, Terry PB, Delisser HM, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med. 2008;177:912–927.
   PubMed Web of Science ®Google Scholar
• Irwin RS, Corrao WM, Pratter MR. Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy. Am Rev Respir Dis. 1981;123:413–417.
   PubMed Web of Science ®Google Scholar
• Hope-Gill BD, Hilldrup S, Davies C, et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:995–1002.
   PubMed Web of Science ®Google Scholar
• Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med. 2012;157:398–406.
   PubMed Web of Science ®Google Scholar
• Mermigkis C, Stagaki E, Amfilochiou A, et al. Sleep quality and associated daytime consequences in patients with idiopathic pulmonary fibrosis. Med Princ Pract. 2009;18:10–15.
   PubMed Web of Science ®Google Scholar
• Krishnan V, McCormack MC, Mathai SC, et al. Sleep quality and health-related quality of life in idiopathic pulmonary fibrosis. Chest. 2008;134:693–698.
   PubMed Web of Science ®Google Scholar
• Mermigkis C, Bouloukaki I, Antoniou KM, et al. CPAP therapy in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea: does it offer a better quality of life and sleep? Sleep Breath. 2013;17:1137–1143.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Arean PA, Berkeley J, et al. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology. 2012;17:525–532.
   PubMed Web of Science ®Google Scholar
• Roman J, Brown KK, Olson A, et al. An official American thoracic society workshop report: comparative pathobiology of fibrosing lung disorders in humans and domestic animals. Ann Am Thorac Soc. 2013;10:S224–229.
   Google Scholar
• Collard HR, Brown KK, Martinez FJ, et al. Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest. 2014;146:1256–1262.
   PubMed Web of Science ®Google Scholar